NuVasive (NUVA +4.5%) pops on a Baird upgrade to outperfrom. Baird cites its proprietary survey...

|By:, SA News Editor

NuVasive (NUVA +4.5%) pops on a Baird upgrade to outperfrom. Baird cites its proprietary survey of spine/neurosurgeons suggesting spine market dynamics are somewhat flat, but the industry's conversion to lateral lumbar fusion creates an opportunity for NuVasive to gain market share.